Industry Developments

BMI View: The Czech Republic's healthcare reforms will provide additional funding for medical provision, but the majority of new resources will be required for higher salaries and offsetting... 2011-09-09

BMI View: Despite real and continued operating risks to pharmaceutical companies present in Russia, BMI maintains the view that the size and growth potential of the Russian pharmaceutical... 2011-09-02

BMI View: Turkey's pharmaceutical market offers strong growth potential and will continue to be viewed as an attractive market for foreign drugmakers to move into, including the acquisition... 2011-09-02

BMI View: The biosimilar licencing deals signed between Gedeon Richter and Stada are mutually beneficial, lowering the risks and costs associated with drug development and adding to... 2011-08-31

BMI View: It is already well known that US and European drugmakers have been highly vocal in their criticism of the way the Turkish government has introduced drug policy reforms, including... 2011-08-30

BMI View: While 2012 is set to be an unusually difficult year for drugmakers in Central Europe, we maintain our view that the long-term growth potential of this region is favourable,... 2011-08-25

BMI View: Ukraine's medical device market rebounded positively in 2010, with the market projected to return low double-digit growth over BMI's five- and ten-year forecast horizons.... 2011-08-23

BMI View: The immediate ramifications of the resignation of Romanian Health Minister Attila Czeke are limited, but the development is an illustration of the chronic underfunding within... 2011-08-12

BMI View: While certain aspects of Bulgaria's law on medicinal products in human medicine have negative implications for drugmakers operating in the country, we maintain the view that... 2011-08-08

BMI View: We continue to expect Romania's pharmaceutical market to return high single-digit growth in 2011 and 2012. However, weaker than expected drug price inflation in Q211 has resulted... 2011-08-03